Director, Technical Accounting and SOX Compliance jobs in United States
cer-icon
Apply on Employer Site
company-logo

Geron Corporation · 6 hours ago

Director, Technical Accounting and SOX Compliance

Geron Corporation is a commercial biotech company seeking a Director of Technical Accounting and SOX Compliance. The role involves leading the Sarbanes-Oxley compliance program, overseeing technical accounting matters, and serving as a key advisor on accounting policy and internal controls.

BiopharmaBiotechnologyHealth DiagnosticsOncologyPharmaceutical
check
Diversity & Inclusion

Responsibilities

Serve as the subject matter expert on U.S. GAAP and SEC accounting standards applicable to a commercial biotech company
Research, interpret, and document technical accounting conclusions for complex transactions, including revenue recognition, collaboration and licensing arrangements, R&D arrangements, inventory valuation, business combinations, equity compensation, leases, and impairments
Develop and maintain accounting policies and position papers to support audit and regulatory review
Monitor new accounting standards and assess their impact; lead adoption and implementation efforts
Coordinate statutory audits, including planning, execution, and timely completion of local statutory financial statements
Assist with tax compliance processes, including coordination with external tax advisors and review of tax-related accounting matters
Support special projects and process improvements as directed by the Chief Accounting Officer
Assist with the Company’s SOX compliance program, including risk assessment, scoping, control design, documentation, testing, remediation, and certification
Manage and coordinate the outsourced internal audit firm, ensuring timely execution of testing and alignment with Company priorities
Partner with business process owners to identify control gaps, design remediation plans, and drive timely and sustainable resolution
Serve as a key liaison with external auditors related to SOX and internal control matters
Monitor changes in business operations, systems, and organizational structure to assess SOX impact and update control frameworks accordingly
Provide guidance and training to control owners and finance personnel on SOX and accounting matter

Qualification

U.S. GAAPSOX complianceSEC reportingCPAFinancial systemsLeadershipProject managementCommunicationCollaborationProblem solving

Required

Bachelor's degree in Finance, Accounting, Business Administration or related field
CPA required
At least 9 years of progressive experience (a mix of industry and Big 4 experience preferred)
Strong knowledge of U.S. GAAP, SEC reporting, and internal control frameworks (COSO)
Ability to work collaboratively with external auditors
Proven ability to operate effectively in a fast-paced, growing commercial organization
Ability to collaborate with senior leadership, peers and external partners
Excellent written and verbal communication, leadership, and project management skills
Proven ability to navigate and resolve complex, undefined issues with sound financial judgment
Proficiency in financial systems (NetSuite, or similar) and Microsoft Office
Hands-on experience managing SOX 404 programs and working with outsourced internal audit providers

Preferred

Experience in life sciences, biotech, or pharmaceutical industry strongly preferred

Benefits

Medical
Dental
Vision
Life insurance
Flexible spending accounts
Disability insurance
Supplemental health insurance
A 401(k) retirement savings plan
An employee stock purchase plan
A generous time off program that includes the eligibility to accrue 160 hours of vacation during each full year of employment
64 hours of sick leave
9 standard paid holiday days off
Paid leave for certain life events

Company

Geron Corporation

twittertwitter
company-logo
Geron is a biopharmaceutical company that is charting a new course with the goal to deliver innovative treatment options for people living with blood cancer.

Funding

Current Stage
Public Company
Total Funding
$999.54M
Key Investors
Pharmakon Advisors
2024-11-07Post Ipo Debt· $250M
2024-03-19Post Ipo Equity· $150M
2023-01-05Post Ipo Equity· $227.84M

Leadership Team

leader-logo
Harout Semerjian
President & CEO
linkedin
leader-logo
Michelle Robertson
Chief Financial Officer
linkedin
Company data provided by crunchbase